Member Info for LovableLumax

Surely the safety committee will complete its review before the end of the month and if patients are lined up we could have 1 to 3 patients receive first dose soon after

Sheppy, you purport to be wealthy and say you have a decent holding here yet are convinced the share price will fall further and you'll lose money yet you continue to hold. Seems very odd. Odder still is the fact you say you have cash yet you sit posting on here all day. Either a sad, strange person and I'm sorry for you or you're lying.

From Marty McFly’s Twitter -

#AVCT

Above all, FAP clips dox. Dox kills.

Platform is ‘further validated’. The substrate sells. Unequivocally.

Great to see FAPmid data included as well, with the right warhead it looks like pre|CISION could have massive utility

Looking forward to seeing their next candidate

The fact that soluble FAP doesn’t clip the dox is a revelation.

The MoA has been ‘negatively tested’ and it’s indiscriminate. It works.

Wyn, before passing comment perhaps read the posts. CTSFO was asking about the patient who had an unrelated heart issue so had to pull out which was explained on the science day.

Search the website, science day was 23 Feb and the presentation slides and audio on https://avacta.com/investors/investor-resources/

You know it's nearly 1am there?

80, 120 and then C3 160

JT which is surely why licensing out 3996 risky as would smash 6000 sales but you'd need a partner as P3 needed so surely a more modest up front payment but better % of sales

She said over 15 months. That’s what I heard before and having re-listened heard agwin

She said he could receive more cycles and over 15 months on drug. Dec presentation

Spot on GoSushi.

Dox usually administered at 75 mg/m2 every 3 weeks for 6 cycles.

80 mg/m2 of AVA6000 is 54 mg/m2 of dox

160 mg/m2 of AVA6000 is 108 mg/m2 of dox

250 mg/m2 of AVA6000 is 169 mg/m2 of dox

Bella many of these tumours heavily treated so are refractory and remission might be pushing it but stablising the disease for that long a result and without the awful side effects

I suspect higher doses will mean fewer cycles but hopefully administered fortnightly and as a first line treatment might mean lots of tumours destroyed so max cumulative dose not needed. That said given the usual response rate for STS with normal dox having PFS for many more months and with a much better quslity of life a superb result. I hope many signs of efficacy will be demonstrated in fortnightly.

There is a max cumulative dose for dox (and other anthracyclines) so they will hae looked at the PK data and established how many cycles the patient is able to have. Usually it's 6 cycles over 4.5 months (3 week cycles) whereas they were able to dose for over 15 months (stabilised disease) and remember without the nasty side effects which is superb. One hopes as a first line treatment and fortnightly will see even better results

Yep, apologies I meant won’t sign off without a going concern which always leads to a large fall. They’d want money sorted before prelims and of course positive data at AACR without a strong balance sheet will mean a rise quickly sold into and then likely a fall due to distressed raise (even more so!). At least now even with the shocking raise there should be a base and decent data with positive commentary rather than fluff should mean a decent rise and a licensing deal H1 will mean a very decent rise. I’m sure AS desperate for that before the AGM

Can be paid in cash and should be if the strike price is below 50p. I hope a positive AACR will have this move a fair whack higher so payment in shares I suspect

wynd - given avct had £16m in the bank there was no immediate pressing need to do the raise last month,

the above is not true. they had £16m end of jan so come end of april it will be a little over £10m and the auditor will not sign off the accounts as you need 12 months cash. i assume they had a deal that fell through so got completely shafted on the raise and ended up being forced to take 50p which is poor on the bod but they had to do so and although as a lth i am ****ed i am happy they now have over £40m in cash so 2 years and i suspect fortnightly will produce some amazing results and large cos more likely to move then so autumn or so. in the meantime aarc should be an eye opener and i am sure there wilk be several patients from cohort 3 to 6 with 6 months plus of treatment which is an improvement on the usual 6 cycles of dox over 4.5 months. also with cash they are in a better negotiatoing position as agreeing to a poor license deal sets a low bar.

Https://avacta.com/investors/corporate-governance/#evaluation_performance

Directors are subject to re-election at the Annual General Meeting following their appointment. In addition, at each Annual General Meeting one third (or whole number more than one third) of the Directors will retire by rotation.

How do you know CC has the commercial acumen? She's surely a very well suited in her current position which is crucial. If AS doesn't pull something remarkable out of the bag and has to go they'll need a more commercially savvy operator who has experience of growing PLCs from £100m market cap to £bns. Managing a smaller PLC and getting more modest raises away very different to where we are and even more so will be in 12 months or so. Anyway, here's hoping we have amazing data quickly followed by a deal to strengthen the balance sheet and validate the platform and the share price will respond and sentiment change. An interesting month or so ahead for definite.